Posaconazole
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antifungals | Posaconazole | Normal dose based on indication | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 701 | <0.2 | 35 | N/A | >98 | 6.6-25.3 (based on 70 kg) | 1415 | 0 (N/A) |
References:
- Cota J, Burgess D. Antifungal Dose Adjustment in Renal and Hepatic Dysfunction : Pharmacokinetic and Pharmacodynamic Considerations. Curr Fungal Infect Rep 2010; 4, 120-128.
- Courtney R, Sansone A, Smith W et al. Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease. Journal of Clinical Pharmacology 2005; 45, 185-92.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01263